Wilmington Savings Fund Society FSB Grows Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Wilmington Savings Fund Society FSB grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 68.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,601 shares of the company’s stock after purchasing an additional 651 shares during the period. Wilmington Savings Fund Society FSB’s holdings in TransMedics Group were worth $100,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Quarry LP lifted its holdings in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI raised its holdings in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after acquiring an additional 316 shares during the last quarter. Hager Investment Management Services LLC purchased a new position in TransMedics Group in the 4th quarter worth approximately $33,000. Finally, Sachetta LLC purchased a new position in TransMedics Group in the 4th quarter worth approximately $40,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 7.00% of the company’s stock.

TransMedics Group Trading Up 2.4 %

Shares of TMDX stock opened at $71.22 on Friday. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a fifty day moving average price of $65.69 and a 200-day moving average price of $107.72. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market cap of $2.39 billion, a price-to-earnings ratio of 75.77 and a beta of 2.12.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on TMDX shares. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Robert W. Baird decreased their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. TD Cowen decreased their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. Finally, Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.